Cat. # | Size | Qty. | Price | Inventory |
---|---|---|---|---|
98322T | 1 Kit (9 x 20 microliters) |
|
Product Includes | Quantity | Applications | Reactivity | MW(kDa) | Isotype |
---|---|---|---|---|---|
Bax (D2E11) Rabbit mAb 5023 | 20 µl |
|
H | 20 | Rabbit IgG |
Bak (D4E4) Rabbit mAb 12105 | 20 µl |
|
H M R Mk | 25 | Rabbit IgG |
Bok (D7V2N) Rabbit mAb 86875 | 20 µl |
|
H | 22 | Rabbit IgG |
Bim (C34C5) Rabbit mAb 2933 | 20 µl |
|
H M R | 12, 15, 23 | Rabbit IgG |
Bad (D24A9) Rabbit mAb 9239 | 20 µl |
|
H M R Mk | 23 | Rabbit IgG |
BID Antibody 2002 | 20 µl |
|
H | 15, 22 | Rabbit |
Puma (D30C10) Rabbit mAb 12450 | 20 µl |
|
H | 23 | Rabbit IgG |
Noxa (D8L7U) Rabbit mAb 14766 | 20 µl |
|
H | 10 | Rabbit IgG |
Bik Antibody 4592 | 20 µl |
|
H | 20 | Rabbit |
Anti-rabbit IgG, HRP-linked Antibody 7074 | 100 µl |
|
Rab | Goat |
Product Information
Monoclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues surrounding Leu45 of human Bax, Gly75 of human Bak, Val88 of human Bok, Pro25 of human Bim, Pro102 of human Bad, Leu45 of human Bax, Pro25 of human Bim, residues near the carboxy terminus of human Puma, and residues near the amino terminus of human Noxa. Polyclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to the amino-terminus of human Bik or residues surrounding the cleavage site of human BID. Polyclonal antibodies are purified by protein A and peptide affinity chromatography.
The Bcl-2 family consists of a number of evolutionarily conserved proteins containing Bcl-2 homology domains (BH) that regulate apoptosis through control of mitochondrial membrane permeability and release of cytochrome c (1-3). Four BH domains have been identified (BH1-4) that mediate protein interactions. The family can be separated into three groups based upon function and sequence homology: pro-survival members include Bcl-2, Bcl-xL, Mcl-1, A1 and Bcl-w; pro-apoptotic proteins include Bax, Bak and Bok; and "BH3 only" proteins Bad, Bik, Bid, Puma, Bim, Bmf, Noxa and Hrk. Interactions between death-promoting and death-suppressing Bcl-2 family members has led to a rheostat model in which the ratio of pro-apoptotic and anti-apoptotic proteins controls cell fate (4). Thus, pro-survival members exert their behavior by binding to and antagonizing death-promoting members. In general, the "BH3-only members" can bind to and antagonize the pro-survival proteins leading to increased apoptosis (5). While some redundancy of this system likely exists, tissue specificity, transcriptional and post-translational regulation of many of these family members can account for distinct physiological roles.
Explore pathways related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.